Today, genomic technologies have revolutionized toxicological assessments and biomarker applications. These methodologies have enhanced the accuracy of gene expression profiling, which has become crucial for understanding drug mechanisms and identifying safety biomarkers. Gene expression analysis is an approach to quantify RNA transcripts that help determine differentially expressed genes. This approach serves as a predictive biomarker for toxicity observations. The advanced capabilities of copy number variation assays and digital PCR analysis offer precise and accurate quantitative data critical for regulatory submissions.
Specialized platforms support comprehensive toxicity studies through reliable validation protocols and biomarker identification initiatives. This article dives into molecular technologies, service applications, and GLP implementation strategies for biomarker discovery.
Fundamentals of GLP studies
Table of Contents
Since 1978, Good Laboratory Practices (GLP) have been critical for ensuring the highest quality in drug development. However, they are not necessarily required in early toxicological evaluations. Non-GLP studies employed at early stages offer significant advantages to researchers and drug developers.
In 1978, the US FDA issued guidance in response to inferior quality and scientific integrity in nonclinical studies. Several years later, the OECD adopted these guidelines to promote GLP practices worldwide. The primary reason for this effort was to increase the level of data acceptance across borders. Since then, GLP guidelines have ensured that nonclinical testing and safety studies are effectively planned, monitored, recorded, reported, and archived. GLP regulations are needed for most nonclinical studies, including tests conducted for IND submissions.
Gene expression analysis for biomarker studies
Today, global Gene Expression Analysis is helping researchers obtain significant data about the state and nature of cells, including pharmacological responses, biological phenomena, and disease progression. These findings often relate to a set of genes and pathways associated with disease-induced changes in state. Additionally, these findings also lead to the identification of gene sets relevant to disease prognosis and outcomes. In several cases, only a small fraction of genes respond statistically. This number further reduces when redundant genes are removed. The resulting subset is an authentic diagnosis signature of the biological state.
Gene expression signatures are proving to be a robust and powerful tool for drug discovery and disease diagnosis. For example, microarray analysis is employed widely for diagnosing and classifying cancers, including prostate and kidney cancers. They are implemented to categorize responses and direct chemotherapy decisions, such as in acute myeloid leukemia. As mentioned above, the data generated from these studies often relates to a small gene pool, which can be used for diagnosis.
Microarray systems are also employed in research applications, including functional genomics coupled with siRNA, pharmacology and toxicity assessments, and developmental genetics. For pharmacology and toxicity evaluations, several studies have analyzed gene expressions relevant to treatment or dosing with different pharmacological agents. On the other hand, in oncology, these microarray systems have discovered a small set of gene signatures that can provide data on specific responses such as hepatotoxicity, cytotoxicity, and genotoxicity.
Although gene expression analysis used in biomarker discovery offers insights and powerful information to accelerate drug development timelines, the depth of information generated is extraordinary, needing sophisticated approaches to yield maximum benefits. Hence, it is vital to access bioinformatics and experimental expertise, along with advanced tools to enable commercial and research applications.
Must Read: Cell Cytotoxicity Assays in Toxicology: Ensuring Drug Safety
Regulatory compliance in gene expression analysis for biomarker studies
Establishing a proper testing environment is necessary for examinations, where signature discovery is used to identify biomarkers for clinical studies and diagnostics. Researchers intending to submit data for IND and NDA submissions should begin before the preclinical stage. On the other hand, if scientists and drug developers plan studies with regulatory compliance, an early focus on regulatory requirements during the discovery phase will lead to a smoother and cost-efficient generation of data downstream.
The crucial component is creating precedent data. This data is generated during the discovery period for regulatory complaint setups. For NDA and IND submissions, studies conducted with GLP regulations have several advantages. These compliances will avoid the need to reconstruct studies developed in the discovery phase. Most importantly, GLP compliance ensures the generation of reliable data in the future with the same degree of specificity, sensitivity, reproducibility, and accuracy.
For clinical applications, precedent data obtained in a GLP-compliant environment leads to a more supportive and reliable transition across the entire drug development cycle. This smooth transition allows drug developers to initiate acquiring research-use-only or investigational-use-only baseline information for patients early during drug discovery that may be exploited later after drug approval. Such approaches ensure that the generated results do not risk losing historical data and the need for data regeneration.
Conclusion
Gene expression analysis has had a transformative impact on advancing biomarker discovery and regulatory capabilities. Systems such as ddPCR gene expression and digital PCR analysis platforms provide reliable biomarker data for experiments, including Tox Studies and copy number variation assays. A comprehensive digital PCR service enhances the quality of regulatory submissions. Hence, a strategic approach to molecular biomarker technologies will improve safety assessments and accelerate drug development projects.
Author
